[{"id":"a3d44513-3d22-4617-a3e3-b78c69f0ade8","acronym":"SGNB7H4V-001","url":"https://clinicaltrials.gov/study/NCT05194072","created_at":"2022-01-18T12:54:03.783Z","updated_at":"2024-07-02T16:34:27.305Z","phase":"Phase 1","brief_title":"A Study of SGN-B7H4V in Advanced Solid Tumors","source_id_and_acronym":"NCT05194072 - SGNB7H4V-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e felmetatug vedotin (PF-08046048)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-11"},{"id":"cb5da6dd-a9b6-436a-acd6-01685f4f5bc2","acronym":"ETHAN","url":"https://clinicaltrials.gov/study/NCT05501704","created_at":"2022-08-15T12:10:47.553Z","updated_at":"2024-07-02T16:34:37.326Z","phase":"Phase 2","brief_title":"ETHAN - ET for Male BC","source_id_and_acronym":"NCT05501704 - ETHAN","lead_sponsor":"Jose Pablo Leone","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2036","study_completion_date":" 04/01/2036","last_update_posted":"2024-06-07"},{"id":"ded04c2b-2ead-4cff-9660-0481bc077bfe","acronym":"MORPHEUS","url":"https://clinicaltrials.gov/study/NCT03280563","created_at":"2021-01-18T16:11:59.285Z","updated_at":"2024-07-02T16:34:37.795Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","source_id_and_acronym":"NCT03280563 - MORPHEUS","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/26/2017","start_date":" 12/26/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"8637b136-3de4-40fa-8293-aa26c472595a","acronym":"SERENA-6","url":"https://clinicaltrials.gov/study/NCT04964934","created_at":"2021-07-16T13:53:17.689Z","updated_at":"2024-07-02T16:34:59.080Z","phase":"Phase 3","brief_title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","source_id_and_acronym":"NCT04964934 - SERENA-6","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 04/25/2025","primary_completion_date":" 04/25/2025","study_txt":" Completion: 11/26/2027","study_completion_date":" 11/26/2027","last_update_posted":"2024-06-04"},{"id":"41c79a8f-32f5-4120-a3a7-4d561141ced0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04553133","created_at":"2021-01-18T21:46:10.057Z","updated_at":"2024-07-02T16:35:03.345Z","phase":"Phase 1/2","brief_title":"PF-07104091 as a Single Agent and in Combination Therapy","source_id_and_acronym":"NCT04553133","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • tegtociclib (PF-07104091)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 03/06/2025","primary_completion_date":" 03/06/2025","study_txt":" Completion: 03/06/2025","study_completion_date":" 03/06/2025","last_update_posted":"2024-05-16"},{"id":"e915b737-ffd0-45cb-831e-4df90b73590c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02206984","created_at":"2021-01-18T10:20:00.102Z","updated_at":"2024-07-02T16:35:03.969Z","phase":"Phase 2","brief_title":"Endocrine Response in Women With Invasive Lobular Breast Cancer","source_id_and_acronym":"NCT02206984","lead_sponsor":"Priscilla McAuliffe","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-14"},{"id":"ce3343fa-10fb-4d25-ac60-a52a8f5d035a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05374915","created_at":"2022-05-16T12:54:38.932Z","updated_at":"2024-07-02T16:35:04.494Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","source_id_and_acronym":"NCT05374915","lead_sponsor":"Kintara Therapeutics, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REM-001 therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/12/2024","start_date":" 02/12/2024","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-10"},{"id":"e31d34ce-d629-43fc-8476-902e52be16d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913440","created_at":"2023-06-22T19:11:36.361Z","updated_at":"2024-07-02T16:35:04.319Z","phase":"","brief_title":"HER2-low Unresectable and/or Metastatic Breast Cancer in Russia","source_id_and_acronym":"NCT05913440","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PTEN mutation + HR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 2450","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-10"},{"id":"80a15019-c76b-402b-869e-abfd7ab973d5","acronym":"PRO1184-001","url":"https://clinicaltrials.gov/study/NCT05579366","created_at":"2022-10-13T16:56:38.872Z","updated_at":"2024-07-02T16:35:06.017Z","phase":"Phase 1/2","brief_title":"PRO1184 for Advanced Solid Tumors","source_id_and_acronym":"NCT05579366 - PRO1184-001","lead_sponsor":"ProfoundBio US Co.","biomarkers":" HER-2 • FOLR1","pipe":" | ","alterations":" HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Rina-S (rinatabart sesutecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 12/07/2022","start_date":" 12/07/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-05-03"},{"id":"8e698f4d-2a78-42c5-a620-76e572d7431e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595059","created_at":"2021-01-18T17:40:37.713Z","updated_at":"2024-07-02T16:35:05.958Z","phase":"Phase 1","brief_title":"A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors","source_id_and_acronym":"NCT03595059","lead_sponsor":"AbbVie","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 07/13/2018","start_date":" 07/13/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-03"},{"id":"78b6125a-a5c5-4d81-93da-53f96c3055b7","acronym":"TIFA","url":"https://clinicaltrials.gov/study/NCT05090358","created_at":"2021-10-22T12:53:12.267Z","updated_at":"2024-07-02T16:35:09.806Z","phase":"Phase 2","brief_title":"Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer","source_id_and_acronym":"NCT05090358 - TIFA","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HR positive • HER-2 negative • PIK3CA mutation • PTEN mutation + HR positive","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PIK3CA mutation • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 10/08/2024","primary_completion_date":" 10/08/2024","study_txt":" Completion: 10/08/2024","study_completion_date":" 10/08/2024","last_update_posted":"2024-04-12"},{"id":"7ce382c5-c733-46c1-a191-5c9b114e6676","acronym":"UNIRAD","url":"https://clinicaltrials.gov/study/NCT01805271","created_at":"2021-01-18T08:00:01.329Z","updated_at":"2024-07-02T16:35:10.322Z","phase":"Phase 3","brief_title":"Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy","source_id_and_acronym":"NCT01805271 - UNIRAD","lead_sponsor":"UNICANCER","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1278","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2024-04-10"},{"id":"9aadf531-8318-4832-8952-5f14a3219c22","acronym":"ALPINIST","url":"https://clinicaltrials.gov/study/NCT05631795","created_at":"2022-11-30T17:57:33.307Z","updated_at":"2024-07-02T16:35:13.783Z","phase":"Phase 4","brief_title":"Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment","source_id_and_acronym":"NCT05631795 - ALPINIST","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HR positive • HER-2 negative • PIK3CA mutation • PTEN mutation + HR positive","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PIK3CA mutation • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/03/2025","study_completion_date":" 11/03/2025","last_update_posted":"2024-03-20"},{"id":"d460cb48-700b-4991-84e5-f141a6a20718","acronym":"","url":"https://clinicaltrials.gov/study/NCT03990896","created_at":"2021-01-18T19:37:18.270Z","updated_at":"2024-07-02T16:35:13.950Z","phase":"Phase 2","brief_title":"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial","source_id_and_acronym":"NCT03990896","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2 • BRCA1 • BRCA","pipe":" | ","alterations":" BRCA1 mutation • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • PTEN mutation + HR positive","tags":["HER-2 • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-19"},{"id":"2d3dd235-1c39-472f-8f34-e54cae81a145","acronym":"DAWNA-FES","url":"https://clinicaltrials.gov/study/NCT05861830","created_at":"2023-05-17T14:05:14.871Z","updated_at":"2024-07-02T16:35:15.108Z","phase":"Phase 3","brief_title":"Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)","source_id_and_acronym":"NCT05861830 - DAWNA-FES","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • tamoxifen • capecitabine • fulvestrant • AiRuiKang (dalpiciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-03-12"},{"id":"2a13790b-df30-4d16-94bd-4e9b80cce1c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05098210","created_at":"2021-10-28T17:56:20.511Z","updated_at":"2024-07-02T16:35:22.189Z","phase":"Phase 1","brief_title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer","source_id_and_acronym":"NCT05098210","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • BRAF • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • BRAF • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-01-25"},{"id":"8b53a2b0-726f-488a-ad4e-487b5d2d48cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04895761","created_at":"2021-05-20T11:54:08.701Z","updated_at":"2024-07-02T16:35:22.223Z","phase":"Phase 1","brief_title":"Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer","source_id_and_acronym":"NCT04895761","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • letrozole • maveropepimut-S (MVP-S) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 09/10/2021","start_date":" 09/10/2021","primary_txt":" Primary completion: 06/16/2023","primary_completion_date":" 06/16/2023","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-01-25"},{"id":"2f08fbe6-a3bd-4df8-b1a3-43fb32cfa623","acronym":"CTMX-2009-002","url":"https://clinicaltrials.gov/study/NCT04596150","created_at":"2021-01-19T20:30:03.686Z","updated_at":"2024-07-02T16:35:22.560Z","phase":"Phase 2","brief_title":"Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer","source_id_and_acronym":"NCT04596150 - CTMX-2009-002","lead_sponsor":"CytomX Therapeutics","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 12/29/2020","start_date":" 12/29/2020","primary_txt":" Primary completion: 06/02/2023","primary_completion_date":" 06/02/2023","study_txt":" Completion: 06/02/2023","study_completion_date":" 06/02/2023","last_update_posted":"2024-01-23"},{"id":"41dc0dc5-5e4a-4f14-83b1-f68418f88664","acronym":"","url":"https://clinicaltrials.gov/study/NCT02965950","created_at":"2021-01-18T14:34:42.467Z","updated_at":"2024-07-02T16:35:23.603Z","phase":"Phase 2","brief_title":"The p53 Breast Cancer Trial","source_id_and_acronym":"NCT02965950","lead_sponsor":"Haukeland University Hospital","biomarkers":" HER-2 • TP53","pipe":" | ","alterations":" TP53 mutation • HR positive • HER-2 negative • TP53 wild-type • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HR positive • HER-2 negative • TP53 wild-type • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2024-01-12"},{"id":"82fc4ba9-d2eb-44d9-885d-9012d52f5a8a","acronym":"ELEMENT","url":"https://clinicaltrials.gov/study/NCT06201234","created_at":"2024-01-11T22:20:22.017Z","updated_at":"2024-07-02T16:35:23.743Z","phase":"Phase 2","brief_title":"Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06201234 - ELEMENT","lead_sponsor":"German Breast Group","biomarkers":" HER-2 • BRCA1","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • PTEN mutation + HR positive","tags":["HER-2 • BRCA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Orserdu (elacestrant)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 03/31/2024","start_date":" 03/31/2024","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-01-11"},{"id":"78019614-1961-4f78-99fd-3f5ab6561a1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05736367","created_at":"2023-02-21T15:01:13.339Z","updated_at":"2024-07-02T16:35:23.950Z","phase":"","brief_title":"Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05736367","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 04/15/2024","start_date":" 04/15/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-01-10"},{"id":"289a0618-cfcf-427b-88ef-2f76601adb15","acronym":"PEPSI","url":"https://clinicaltrials.gov/study/NCT05303129","created_at":"2022-03-31T18:52:57.246Z","updated_at":"2024-07-02T16:35:24.117Z","phase":"","brief_title":"Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.","source_id_and_acronym":"NCT05303129 - PEPSI","lead_sponsor":"Centre Francois Baclesse","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PTEN mutation + HR positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 05/27/2022","start_date":" 05/27/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-01-09"},{"id":"10bc779c-5572-474d-b02c-73d1d2b1bbd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05365178","created_at":"2022-05-09T12:56:45.634Z","updated_at":"2024-07-02T16:35:24.870Z","phase":"Phase 3","brief_title":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","source_id_and_acronym":"NCT05365178","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Saitanxin (culmerciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 432","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-12-29"},{"id":"97d926d0-be37-423b-83a2-cb239072fda6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05464810","created_at":"2022-07-19T14:54:34.432Z","updated_at":"2024-07-02T16:35:27.090Z","phase":"Phase 1","brief_title":"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05464810","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA • IL10 • TGFB1","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR • IL6 • TNFA • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2023-12-05"}]